聚焦超声丘脑毁损术治疗八旬以上特发性震颤
3个月时TETRAS评分平均改善9.2分,患者自报震颤缓解平均81%,不良事件轻微且短暂。结论认为该无创治疗对高龄患者安全有效。
要点
- ≥80岁药物难治性特发性震颤患者可考虑单侧MRgHIFU丘脑毁损术。
- 3个月TETRAS评分平均改善9.2分,患者自报震颤缓解平均81%。
- 不良事件轻微短暂,非手术相关不良事件率1.6%。
核心结论
- 单侧MRgHIFU丘脑毁损术是≥80岁特发性震颤患者安全有效的无创治疗,震颤与残疾显著改善且并发症率低。
研究设计与样本
- 回顾性多中心队列研究,纳入2016至2023年五家学术神经外科中心连续≥80岁药物难治性特发性震颤患者,均符合颅骨密度比标准并接受标准化靶向。
主要发现
- 3个月时TETRAS评分平均改善9.2分(p < 0.001)。
- CRST评分亦显著改善,患者自报震颤缓解平均81%。
- 不良事件轻微且短暂,非手术相关不良事件率为1.6%。
- 80-84岁与≥85岁亚组治疗反应无显著差异,≥85岁组步态结局改善 modest 但不显著。
关键数值与推荐
- 主要结局为TETRAS评估的震颤严重程度变化。
- 次要结局包括CRST评分、动态步态指数、患者自报震颤缓解及不良事件。
临床怎么用
- 对于因合并症不适合深部脑刺激等侵入性操作的≥80岁特发性震颤患者,可考虑单侧MRgHIFU丘脑毁损术。
局限性
- 回顾性研究设计。
- 随访仅至3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Essential tremor (ET) is common and disabling in older adults. Many patients aged ≥ 80 years are ineligible for deep brain stimulation due to medical comorbidities. Data on noninvasive alternatives, such as MR-guided high-intensity focused ultrasound (MRgHIFU), remain limited in this population. The aim of this study was to evaluate the safety and efficacy of unilateral MRgHIFU thalamotomy targeting the ventral intermediate nucleus (VIM) for the treatment of ET in patients ≥ 80 years of age. METHODS: This retrospective multicenter cohort study included consecutive patients aged ≥ 80 years with medically refractory ET treated with unilateral MRgHIFU VIM thalamotomy between 2016 and 2023 at five academic neurosurgical centers. All patients met skull density ratio criteria and underwent standardized targeting. Clinical assessments were conducted at baseline, immediately posttreatment, and at the 3-month follow-up. The primary outcome was change in tremor severity assessed by using the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS). Secondary outcomes included the Clinical Rating Scale for Tremor (CRST) score, Dynamic Gait Index score, patient-reported tremor relief, and adverse events. RESULTS: One hundred twenty-nine patients (76 male, mean age 84 years) were included. At 3 months, the mean TETRAS score improved by 9.2 points (p < 0.001). CRST scores also showed significant improvement. The mean patient-reported tremor relief was 81%. Adverse events were mild and transient, with a 1.6% rate of nonsurgical adverse events. Subgroup analysis comparing patients 80-84 years versus those ≥ 85 years of age showed no significant differences in treatment response. Gait outcomes improved modestly but were not significant in the age ≥ 85 years group. CONCLUSIONS: Unilateral MRgHIFU thalamotomy is a safe and effective noninvasive treatment for ET in patients ≥ 80 years of age. It results in significant improvements in tremor and disability, with a low complication rate. These findings support its consideration for older patients who are ineligible for invasive procedures and highlight the importance of age-specific metrics in neuromodulation outcomes research.
引用
- Panchawagh S, Santini V, Ranjan M, et al. Focused ultrasound thalamotomy for essential tremor in octogenarians. J Neurosurg. 2026. PMID: 41996720. doi:10.3171/2025.12.JNS251973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。